Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Woman seeing her physician

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

Debunking Myths about the Enhanced ACA Tax Credits

October 11, 2024

This factsheet seeks to debunk some of the misinformation that has been made about the enhanced ACA tax credits.

ACS CAN Factsheet: Why Congress Must Act Swiftly on Enhanced ACA Tax Credits

October 9, 2024

This factsheet provides background information on why Congress must acti swiftly to extend the enhanced ACA tax credits. 

ACS CAN Factsheet: Enhanced ACA tax credits have helped historically marginalized communities

October 9, 2024

This factsheet shows how the enhanced ACA tax credits have benefitted historically marginalized communities. 

View All Access to Health Care Resources

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

ACS CAN Comments on FDA Draft Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies

September 28, 2024

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.

ACS CAN supports the Medicare Multi-Cancer Early Detection Screening Coverage Act (HR 2407/S 2085)

June 20, 2024

Multi-Cancer Screening Tests Can Catch Cancer Early

ACS CAN Supports the Clinical Trial Modernization Act (H.R. 8412)

May 15, 2024

The Clinical Trial Modernization Act (H.R. 8412) would increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food and lodging.

View All Research, Funding and Drug Development Resources

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

ACS CAN & Federal Tobacco Litigation - An Overview

October 25, 2024

The tobacco industry has a history of using litigation to avoid and delay laws and regulations enacted to safeguard the public. ACS CAN, with our tobacco control partners, has also relied on the courts to hold Big Tobacco accountable and to ensure the federal government is effectively implementing the Tobacco Control Act.

Delayed Implementation of Graphic Warning Labels on Cigarettes Harms Public Health

October 25, 2024

Implementation of graphic warnings in the U.S. has been thwarted by tobacco industry legal challenges. The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN), along with our partners, have fought back in the judicial system, using litigation to both compel the U.S. Food and Drug Administration (FDA) to issue graphic warning regulations and help the U.S. Department of Justice (DOJ) defend the regulations finalized by FDA.

The National Breast & Cervical Cancer Early Detection Program

August 8, 2024

For 30 years, the Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program has decreased disparities in breast and cervical cancer deaths.

View All Prevention and Early Detection Resources

Doctor and Patient

Health Equity

ACS CAN supports health equity efforts for all Americans so they may receive access to quality care, no matter their race, ethnicity, sexual orientation, income level or ZIP code. 

ACS, ACS CAN and Partners Joint Comments on Patient Navigation Provisions of CY2025 Medicare Physician Fee Schedule Proposed Rule

September 9, 2024

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2025 Medicare Physician Fee Schedule.

Sustainably Funding Patient Navigation

April 9, 2024

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) are united in the goal of achieving health equity and access to quality care across the cancer continuum through effective patient navigation. Yet to date, patient navigation services are still absen

Addressing Cancer Disparities in LGBTQ+ Communities

March 20, 2024

A critical factor for eliminating disparities and ensuring health equity is the guarantee that all people have access to quality, affordable health care.

View All Health Equity Resources